A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Recruiting · Phase 3 · NCT06943872
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $563,925
- U.S. investigators named
- 9
- Sites paid
- 9
- Planned or actual enrollment
- 630
About the trial
- Sponsor
- BeOne Medicines (with German CLL Study Group)
- Tested
- Sonrotoclax (drug), Obinutuzumab (drug), Rituximab (drug), Venetoclax (drug)
- Dates
- Started 2025-06-11; completion 2031-12
- Results posted
- Not yet
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.
From ClinicalTrials.gov, last updated 2026-10-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $563,925 in research payments for this study in 2025 (72 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Catherine C. Coombs, M.D. Hematology & Oncology · Orange, CA
- Bita Fakhri, M.D., M.P.H Hematology · Palo Alto, CA
- Scott F. Huntington, M.D. Hematology & Oncology · New Haven, CT
- Brett T. Brinker, MD Hematology & Oncology · Grand Rapids, MI
- Sameer A. Parikh, M.D. Hematology · Rochester, MN
- Ryan W. Jacobs, MD Hematology · Charlotte, NC
- James D'olimpio Hematology & Oncology · Lake Success, NY
- Jeff P. Sharman, M.D. Medical Oncology · Eugene, OR
- Michael T. Byrne, D.O. Hematology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Board of Trustees of the Leland Stanford Junior University $327,169
- Mayo Clinic Hospital Rochester, MN $92,138
- Wake Forest University Health Sciences $74,246
- Clinical Research Alliance, Inc. $28,875
- Cancer and Hematology Centers of Western Michigan, PC $26,850
- Uci Health-Orange, CA $4,283
- Florida Cancer Specialist (scri) - Fort Myers $4,283
- Scri Tennessee Oncology Chattanooga $4,283
- Yale University $1,800
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.